Temporally designed treatment of melanoma cells by ATRA and polyI: C results in enhanced chemokine and IFNβ secretion controlled differently by TLR3 and MDA5

Melanoma Research

Volumn 22, Issue 5, 2012, Pages 351-361

  Szabo, Attila ^a   Osman, Rolah M ^a   Bacskai, Ildiko ^a   Kumar, Brahma V ^a   Agod, Zsofia ^a   Lanyi, Arpad ^a   Gogolak, Peter ^a   Rajnavolgyi, Eva ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

chemokines; MDA5; toll like receptor 3; type I interferon

Indexed keywords

BETA INTERFERON; CXCL1 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MELANOMA DIFFERENTIATION ASSOCIATED PROTEIN 5; MESSENGER RNA; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN; RETINOIC ACID; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; DENDRITIC CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; INTERFERON PRODUCTION; MELANOMA CELL; NEUTROPHIL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CHEMOKINES; DRUG SYNERGISM; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERFERON INDUCERS; INTERFERON-BETA; MACROPHAGES; MELANOMA; POLY I-C; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TOLL-LIKE RECEPTOR 3; TRANSCRIPTOME; TRETINOIN;

EID: 84866242485     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328357076c     Document Type: Article

References (39)

1. Sharma P,Wagner K,Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011; 11:805-812.
2. Eggermont AM, Robert C. New drugs in melanoma: it's a whole new world. Eur J Cancer 2011; 47:2150-2157.
3. Sullivan RJ, Atkins MB. Cytokine therapy in melanoma. J Cutan Pathol 2010 (Suppl 1):S60-S67.
4. Aamdal S. Current approaches to adjuvant therapy of melanoma. Eur J Cancer 2011; 47 (Suppl 3):S336-S337.
5. Roman RA. Immunotherapy for advanced melanoma. Clin J Oncol Nurs 2011; 15:E58-E65.
6. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol 2009; 9:679-691.
7. Merad M, Ginhoux F, Collin M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol 2008; 8:935-947.
8. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34:637-650.
9. Benko S, Magyarics Z, Szabo A, Rajnavolgyi E. Dendritic cell subtypes as primary targets of vaccines: the emerging role and cross-talk of pattern recognition receptors. Biol Chem 2008; 389:469-485. (Pubitemid 351874188)
10. Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann NY Acad Sci 2008; 1143:1-20.
11. Gonzalez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012; 12:125-135.
12. Caraglia M, Marra M, Tagliaferri P, Lamberts SW, Zappavigna S, Misso G, et al. Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. Curr Cancer Drug Targets 2009; 9:690-704.
13. Albanesi C, Scarponi C, Giustizieri ML, Girolomoni G. Keratinocytes in inflammatory skin diseases. Curr Drug Targets Inflamm Allergy 2005; 4:329-334. (Pubitemid 40873120)
14. Lacotte S, Brun S, Muller S, Dumortier H. CXCR3, inflammation, and autoimmune diseases. Ann NY Acad Sci 2009; 1173:310-317.
15. Neville LF, Mathiak G, Bagasra O. The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 1997; 8:207-219. (Pubitemid 28077928)
16. Liu M, Guo S, Hibbert JM, Jain V, Singh N,Wilson NO, et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev 2011; 22:121-130.
17. Amatschek S, Lucas R, Eger A, Pflueger M, Hundsberger H, Knoll C, et al. CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3-mediated activation of melanoma cells. Br J Cancer 2011; 104:469-479.
18. Singh S, Singh AP, Sharma B, Owen LB, Singh RK. CXCL8 and its cognate receptors in melanoma progression and metastasis. Future Oncol 2010; 6:111-116.
19. Antonicelli F, Lorin J, Kurdykowski S, Gangloff SC, Le Naour R, Sallenave JM, et al. CXCL10 reduces melanoma proliferation and invasiveness in vitro and in vivo. Br J Dermatol 2011; 164:720-728.
20. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature 2001; 413:732-738. (Pubitemid 33009951)
21. Yu M, Levine SJ. Toll-like receptor, RIG-I-like receptors and the NLRP3 inflammasome: key modulators of innate immune responses to doublestranded RNA viruses. Cytokine Growth Factor Rev 2011; 22:63-72.
22. Mathe G, Kamel M, Dezfulian M, Halle-Pannenko O, Bourut C. An experimental screening for 'systemic adjuvants of immunity' applicable in cancer immunotherapy. Cancer Res 1973; 33:1987-1997.
23. Cheng YS, Xu F. Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol Ther 2011; 10:1219-1223.
24. Besch R, Poeck H, Hohenauer T, Senft D, Hacker G, Berking C, et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest 2009; 119:2399-2411.
25. Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P. Toll-like receptor expressed by melanoma cells as a target for therapy? Clin Cancer Res 2007; 13:4565-4574. (Pubitemid 47219727)
26. Fujimura T, Nakagawa S, Ohtani T, Ito Y, Aiba S. Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma. Eur J Immunol 2006; 36:3371-3380. (Pubitemid 44932738)
27. Jiang Q,Wei H, Tian Z. Poly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway. BMC Cancer 2008; 8:12-19.
28. Salem ML, Kadima AN, Cole DJ, Gillanders WE. Defining the antigenspecific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunother 2005; 28:220-228. (Pubitemid 40593987)
29. Kast RE. Potential for all-trans retinoic acid (tretinoin) to enhance interferonalpha treatment response in chronic myelogenous leukemia, melanoma, myeloma and renal cell carcinoma. Cancer Biol Ther 2008; 7:1515-1519.
30. Desai SH, Boskovic G, Eastham L, Dawson M, Niles RM. Effect of receptorselective retinoids on growth and differentiation pathways in mouse melanoma cells. Biochem Pharmacol 2000; 59:1265-1275. (Pubitemid 30157889)
31. Zhang H, Satyamoorthy K, Herlyn M, Rosdahl I. All-trans retinoic acid (atRA) differentially induces apoptosis in matched primary and metastatic melanoma cells-a speculation on damage effect of atRA via mitochondrial dysfunction and cell cycle redistribution. Carcinogenesis 2003; 24:185-191. (Pubitemid 36267085)
32. Baroni A, Paoletti I, Silvestri I, Buommino E, Carriero MV. Early vitronectin receptor downregulation in a melanoma cell line during all-trans retinoic acid-induced apoptosis. Br J Dermatol 2003; 148:424-433. (Pubitemid 36461320)
33. Gogolak P, Rethi B, Szatmari I, Lanyi A, Dezso B, Nagy L, et al. Differentiation of CD1a-and CD1a+ monocyte-derived dendritic cells is biased by lipid environment and PPARgamma. Blood 2007; 109:643-652. (Pubitemid 46105965)
34. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006; 441:101-105.
35. Matsumoto M, Seya T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev 2008; 60:805-812.
36. Wang Y, Cella M, Gilfillan S, Colonna M. Cutting edge: polyinosinic:polycytidylic acid boosts the generation of memory CD8 T cells through melanoma differentiation-associated protein 5 expressed in stromal cells. J Immunol 2010; 184:2751-2755.
37. McCartney S, Vermi W, Gilfillan S, Cella M, Murphy TL, Schreiber RD, et al. Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J Exp Med 2009; 206:2967-2976.
38. Szabo A, Bene K, Gogolák P, Ré thi B, Lányi A, Jankovich I, et al. RLR-mediated production of interferon-b by a human dendritic cell subset and its role in virus-specific immunity. J Leukoc Biol 2012; 92:159-169.
39. Xiao HB, Zhou WY, Chen XF, Mei J, Lv ZW, Ding FB, et al. Interferon-beta efficiently inhibited endothelial progenitor cell-induced tumor angiogenesis. Gene Ther 2011